1. Home
  2. ANIP vs INVA Comparison

ANIP vs INVA Comparison

Compare ANIP & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ANI Pharmaceuticals Inc.

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$80.75

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Innoviva Inc.

INVA

Innoviva Inc.

HOLD

Current Price

$21.79

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIP
INVA
Founded
2001
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
1999
2000

Fundamental Metrics

Financial Performance
Metric
ANIP
INVA
Price
$80.75
$21.79
Analyst Decision
Strong Buy
Buy
Analyst Count
5
5
Target Price
$110.00
$32.80
AVG Volume (30 Days)
300.1K
730.9K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
419.23
816.67
EPS
1.28
2.22
Revenue
$206,547,000.00
$217,217,000.00
Revenue This Year
$21.01
$8.95
Revenue Next Year
$17.59
$12.65
P/E Ratio
$63.55
$10.07
Revenue Growth
2.47
62.63
52 Week Low
$62.61
$16.52
52 Week High
$99.50
$25.15

Technical Indicators

Market Signals
Indicator
ANIP
INVA
Relative Strength Index (RSI) 44.05 41.84
Support Level $77.16 $21.51
Resistance Level $83.66 $23.03
Average True Range (ATR) 2.55 0.60
MACD -0.44 -0.09
Stochastic Oscillator 10.29 4.23

Price Performance

Historical Comparison
ANIP
INVA

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

About INVA Innoviva Inc.

Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.

Share on Social Networks: